Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

A resilient XBI index can be deceptive because strong performance among the top 25 names obscures widespread declines across the broader universe. This divergence creates friction with limited partners, who question why specialist managers lag headline biotech benchmarks during apparent market strength.

Related Insights

Benchmark index performance can mislead investors when broad market advances are driven almost entirely by tech, semiconductors, and energy. Portfolios positioned in consumer, industrial, or traditional value sectors experience steep relative underperformance and correction-level frustration despite positive headline index figures.

The XBI is at post-pandemic highs, but this isn't a true reflection of the entire sector. Its methodology shifted from an equal-weight index to one favoring larger, liquid companies. Recent M&A of these larger companies has disproportionately driven the index up, masking the performance of smaller biotechs.

While broad biotech indices performed poorly, the past two years were manageable and even ideal for investors who were highly selective. The downturn created an environment for skilled stock pickers to identify high-quality companies that could withstand market pressures, proving that sector-wide performance is not the whole story.

Despite biotech comprising a significant portion of benchmarks, generalist managers consistently remain severely underweight. They perceive this as risk-averse, but it actually exposes their funds to massive tracking error and unintended risks by forcing them to be overweight in other healthcare sub-sectors.

While the XBI is up significantly, this is driven by under-owned or shorted stocks like Moderna. Meanwhile, the companies most specialist biotech funds actually own are "getting hammered," creating a disconnect between the index's performance and investors' actual portfolio returns.

Although the XBI index gained over 20%, specialized biotech fund managers experienced acute underperformance. The rally was driven by tech or AI stocks that biotech specialists rarely hold, while crowded long positions lagged and heavily shorted names rebounded sharply against fund positions.

Despite the biotech index (XBI) appearing relatively stable, many long-short funds are suffering. This is due to a "degrossing effect" and the underperformance of smaller-cap names within the index. The sector, once seen as impervious to rising interest rates, may now be feeling the pressure.

Contrary to its volatile reputation, the XBI biotech index has been relatively stable. Its recent underperformance compared to the S&P 500 is not due to weakness in biotech, but rather the S&P's own AI-fueled volatility, which created a temporary outperformance that has since corrected.

A closer look at biotech ETFs reveals a bifurcated market recovery. The large-cap weighted IBB is back to its late 2021 peak, but the small-cap focused XBI still lags significantly. This shows that investor capital flowing back into the sector is not lifting all boats equally.

Contrary to typical risk-off behavior, the biotech index (XBI) is outperforming the S&P 500. It shows resilience on down days and outsized gains on up days. This indicates a persistent underlying investor demand for the sector, possibly due to its multi-year underperformance and maturing fundamentals.

Top-Heavy ETF Weighting Masks Severe Pain Among Underlying Biotech Stocks | RiffOn